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ABSTRACT
Variables That Affect the Amount of the Consent That
Clinical Research Subjects Read
by
Joanne Hembree Robinson
Dr. Margaret Louis, Examination Committee Chair
Professor of Nursing
University of Nevada, Las Vegas

Various codes, regulations and guidelines have been established that outline what
information must be provided to human subjects to insure that their participation in
clinical drug studies is informed as well as voluntary. Recently questions have been
raised as to whether written consent forms guarantee participants are making
autonomous, informed decisions. The purpose of this study was to determine how much
of the consent research subjects read in relation to selected variables. Seventy-seven
percent of the participants reported that they read the entire consent form, but results
suggest that 30-40% may not understand the study they are in. A question not answered
is, do research subjects in clinical drug studies know information pertinent to the study in
which they are participating.
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CHAPTER 1

INTRODUCTION
Backgound and Significance
“Any Research Project Utilizing Human Subjects Requires
the Informed Consent of Those Subjects”
(Federal Regulations Governing Human Experimentation, 46.116)
The Doctrine of Informed Consent was created to protect the rights and welfare of
human subjects participating in clinical research. Various ethical codes, federal and state
regulations and professional guidelines have been established that explicity outline what
information must be provided to human subjects to insure that their participation is
informed as well as volimtary (Piper. 1994, Cassidy & Oddi, 1986).
Informed consent is a concept developed from the moral principal of selfdetermination or autonomy ( Roach 1990). “ Autonomy means that persons have the right
to determine their course of action on the basis of a plan that they have developed for
themselves” (Davis, 1989, p.448). Additionally those patients who acquire more
information are able to make better decisions (Beisecker & Beisecker, 1990). “Despite
the fact that many individuals express a desire for more information and involvement in
the health care process, it remains to be seen if they have adopted a more participative
approach by becoming involved in decisions made about their health” (Brashers, Haas &
A.
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actively participate in health care decision making ( Brashers, Haas & Neidig, 1999;
Beisecker & Beisecker, 1990; Hinckly, Craig & Anderson, 1989).
There are several ways to obtain a subject's consent, but almost all o f them
involve written documentation (Federal Regulations Governing Human Experimentation,
46.117(a), so the most common method of obtaining informed consent is through the use
of written consent forms. However, questions recently have been raised as to whether or
not this method guarantees that research subjects are making airtonomous, informed
decisions (Tenthorey, & Dison, 1996; Marwick, 1998; Energy Times, February, 2000).

Problem
A recent article indicated that research subjects typically read less than fifty
percent of a written consent form ( New York Times, May 1999). There are several
results from this: Subjects are not truly knowledgeable about the study they are agreeing
to participate in, dissatisfaction with the consent process, lawsuits by clinical research
subjects (Kaplan & Brownlee, 1999; Las Vegas Review-Joumal, December 9,1999), and
in extreme cases even injury or death (Las Vegas Review-Joumal, May 24,2000).

Sieitificance
The need for the protection o f human subjects involved in research was brought
to the world’s attention after World War H, during the Nuremberg trials. The first effort
to establish formal ethical standards for human subjects research is known as the
Nuremberg Code (Iserson, 1999). Nearly every major ethical code or guideline for
h u m a n r e w a r r h H e w ln n m t c tn r p th e N irre m h e ro tr ia lc h a c h e e n ha«*rf a t le a c t in n a r t n n
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the Nuremberg principles. It is only in the last 20 years that most o f these codes and
guidelines have been enacted (Grundner, 1986).
Despite the existence o f regulations, codes, and guidelines, abuses in human
research continue to take place. In 1963 twenty-two subjects were injected with live
cancer cells without being informed at the Jewish Chronic Disease Hospital in New York
(Grundener, 1986). An audit by the Food and Drug Administration of studies conducted
between 1977 and 1983 revealed that more than 10 percent of clinical drug studies had
deficiencies in one or more o f the following areas: subjects’consent, accountability' for
drugs, adherence to research protocol, and accuracy or availability o f protocols for the
study (Hammerscfamidt, 1992). Recently the problems with patients rights have resulted
in the closure of studies at well-respected universities: Duke and the University of
Pennsylvania (Kaplans & Brownlee, 1999; “FDA: Teen too sick”, 1999).
One of the methods developed to protect the rights of research subjects is the
informed consent document The goal o f this document is to provide potential research
subjects with all the information they need to make an informed autonomous decision
about participating in a research trial.
Nurses working in the field o f clinical research often have the responsibility of
administering the informed consent document and insuring that potential research
participants understand the information in the consent prior to signing i t The problem is
that even with encouragement potential subjects do not always read the entire clinical
drue trial consent form.
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Purpose
The purpose of this study was to identify how much o f the consent form clinical
research subjects read when they agree to participate in clinical drug studies. An
additional goal of this study was to learn more about why research subjects read or do not
read all of a consent form.
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CHAPTER 2

REVIEW OF RELEVANT LITERATURE
Introduction
A review of the relevant literature covering clinical drug studies was conducted to
identify which variables were most likely to have an influence on the amount of the
informed consent that was read. A brief historical overview of the development of
informed consent in clinical drug trials is presented first to give the reader background
on informed consent and protection of subjects rights.

Historical Overview
The Federal government regulates clinical research involving human subjects by
enacting a statute (law) and then delegating to a government agency the responsibility to
define and enact the law by issuance of regulations ( Wing, 1985). These regulations,
authorized by statute, are published (Annas et al., 1981) and implemented under statutory
law. Such regulations are part of that law and violation o f the regulation is a violation of
the law (Wing, 1985).
In the United States federal regulation o f research was originally done by the
Department o f Health, Education and Welfare ( now the Department o f Health and
Human ServicesDEHS). Its actions and authority are in accordance with its powers
under the Public Health Act to regulate the research fcr which it provides funds. The
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Federal Drug Administratioa and the Public Health Service (PHS) are agencies of the
DHHS whose regulations are now the standard for protecting human subjects in the
United States (Veatch, 1987). These regulations go beyond the standards set by the
Nuremberg Code and the Declaration o f Helsinki, specifically regarding the requirement
that all investigations be reviewed by an independent committee prior to being started. In
addition, the FDA establishes standards for the research protocols that it will accept as
evidence o f the safety and efficacy of drugs (Hershey & Miller, 1976).
The Food and Drug Administration (FDA) is the agency responsible for consumer
protection in the use of cosmetics, foods, and drugs, and was the first agency in the
DHHS to regulate clinical investigations. The first congressional policy on informed
consent was the Drug Amendment Act of 1962 that came into being after the
Thalidomide disasters (Oddi & Cassidy, 1998). The Kefauver-Harris amendments of
1962 required that informed consent be obtained fi'om potential human subjects prior to
their participation in the testing of investigational drugs. These amendments were
limited though because the FDA did not want to interfere with doctor-patient relations
and waived consent if the doctor did not believe it was in the patient’s best interest to
know he/she was in a study, or if it was not feasible to gain informed consent from
subjects (ACHRE Report p.l). Formal department policies were published in 1967, and
additional regulations were added in 1971 ( Hersey & Miller, 1976) that covered
potential subjects rights.
In 1974, Title El of the National Research Act was signed into law. This act
established a National Commission for the Protection o f Human Subjects of Biomedical
■■ ■ » « ■
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7
concerning human subjects involved in research sponsored by the federal government
(Veatch, 1987). Proposals by this commission were part of the 1981 regulations
published by the DHHS. This commission also identified three moral principles, known
as the Belmont principles, as the framework for guiding the ethics of research involving
human subjects. The Belmont principles are respect for persons, beneficence, and
justice. The commission was required to examine the “nature and definition” of
informed consent and argued that the basic justification for the obligation to obtain
consent is the moral principle o f respect for persons (ACHRE chapt 3).
In 1995 President Clinton established the National Bioethics Advisory
Commission (NBAC) to review how human subjects rights were protected. The Office
for Protection from Research Risks (OPRR) is within the National Institute of Health
which funds much of the research that OPRR oversees. OPRR was criticized by the
NBAC for its lack of ability to carry out investigations (Marwick, 1998).
In addition to federal standards, professional organizations have established
guidelines for clinical and other research. One organization, The American Nurses’s
Association, has developed standards for nurses conducting research which includes the
“Code for Nurses With Interpretive Statements” and the “ANA’s Human Rights
Guidelines for Nurses in Clinical and Other Research” (ANA Guidelines on Ethical
Values, Nursing Research 1968).
Some states have also developed regulations governing human research, but state
regulations tend to focus on specific issues rather than broad areas. California statutes
are found in the California Penal Code, 1977, and the California Health and Safety Code
1078

M p w V n rlf h a c P iih H r H e a lth I a w e ntiKHchaH in 10 7 ^ r n n r a m in c r h tim a n r a c f a r r h
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One thing that federal laws, state laws and professional guidelines have in common, is
that they all emphasize that research can be conducted only after informed consent is
obtained, which is the “autonomous authorization by individuals of a medical
intervention or of involvement in research” (Beaucham & Childress, p. 143 1994).
The specific federal laws that govern informed consent are found in the Code of
Federal Regulations, Title 21, parts 50,56, and 312, revised April 1,1998. Part 50,
Subpart A defines the scope, what or who the regulations apply to and also gives
definitions. Subpart B deals specifically with the informed consent by human subjects,
general requirements for informed consent, exception from general requirements,
exception from informed consent requirements for emergency research, elements of
informed consent, and documentation o f informed consent Subpart B, 50.20 states that
“no investigator may involve a human being as a subject in research covered by these
regulations unless the investigator has obtained the legally effective informed consent of
the subject or the subject’s legally authorized representative”. Additionally “ the
information given to the subject or the representative shall be in language understandable
to the subject or the representative”. Subpart B, 50.27 states that except in certain cases
outlined in 56.109, informed consent shall be documented by the use of a written consent
form, and either the subject or the subject’s representative shall have adequate
opportunity to read the consent form before it is signed.
The above provisions are pertinent to this paper because they specifically outline
what written information must be given to a potential research subject and how it should
be given. The problem remains, however, that even if adequate information is provided,
S A W A & W X A W X &W W A
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consent. The next sections discuss Actors that have been found to impact
comprehension of what people read.

Comprehension Factors
Informed consent forms are used to convey information to potential research
subjects so they can reach a decision about whether they should participate. Department
of Health and Human Services Regulations for the Protection of Human Subjects require
that study information be presented at a level that is easily understood by the subjects
who will be reading it (Tamowski, Allen, Mayhall and Kelly 1990). The next sections
offer factors that have been identified as affecting reading comprehension and have
potential to prevent or impede a potential subject from reading an informed consent
document and understanding its content.
Readability
Readability is the reading grade level required to understand any given document
(Grundner, 1986) and may influence how much of a consent form is read. Spadero
(1983) foimd comprehension tests showed that about 50% of patients in general were not
able to read, or had difficulty reading instructional materials written at the fifth grade
level or greater. The study findings were that readability of the written patient material
showed most to be above the eight grade level. Goldstein, Fraiser and Curtis (1996)
reviewed 284 consent forms for clinical research and he found that the average form was
written at a twelfth grade level, with less than ten percent written at the tenth grade level
or below. Another study using the Gunning Fog Index and Flesch-Kincaid Formulas for
readability fi^und that 100^*» o f the 137 cori.^nt n,# în^

r;7y^rvh studies analyzed were
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written at grade level 11.1 to 14.1 (Grossman, Piantadosi and Covahey 1994).
Seventy-one consent forms selected from research proposals on IRB agendas had
grade level fifteen as the norm, and of sixty-four proposals approved only eleven had
improved readability as recommended (Hammerschmidt, 1992).
Studies by Lawson and Adamson (1995), LoVerde, Prochazka and Byyny (1989),
Morrow (1980) and Murgatroyd (1991) reached similar conclusions as the before
mentioned studies, that the readability of informed consent material was at a grade level
higher than that attained by the average research subject. Only two studies found no or
only slight problems with readability. An attitudinal survey o f 45 oral surgeons in
Canada found that only 63% percent of their patients could both read and understand
consent forms used by the surgeon (Freedman & Dunn, 1984).
An additional problem with readability is that self-reported educational status
may not accurately reflect actual reading ability. Even when patients correctly report last
grade completed in school this does not indicate actual reading ability (Davis e t al.,
1991, Davis, Long, Jackson, Mayeaus 1993). Patients in studies by Davis, Doak, Jacson
and Gault read four to five grade levels below the last grade they attended ( Murphy,
Cavis, Long, Jackson, Decker 1993).
The importance of readability is that written informed consent documents are
used to covey specific study information. If the information is not at a level that is easily
understood by the potential subjects he/she may not be able to arrive at an informed
decision concerning their willingness to participate.
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Format
A second variable that may influence how much o f the consent form is read is the
format Format refers to the way the consent is arranged and can include type size, order,
spacing, font and style. Taub, Kline, and Baker (1981) discussed size of typeface as a
potential problem for older volunteers. A later smdy by Taub and Sturr (1990) again
identified format problems with older subjects due to vision problems. Length o f the
form has also been found to affect reading in a study of patients in chemotherapy trials
when 75 women were tested for their preferences for short, medium, or long consent
forms. Most patients preferred long forms with more information but those receiving the
long forms had the most difflculty answering basic questions about the study (White,
Muss & Micheiutte, 1984).
Another area identified by Cardinal, Martin and Sachs (1996) was that most
forms were not “user-fiiendly”. That is they do not use formats such as double spacing
and large type size. Epstein and Lasagna (1996) gave consent forms o f different lengths
to 66 subjects, and concluded that comprehension and retention was greatest when the
information was clearly and briefly stated.
A study by Peterson, Clancy, and Champion (1992) used computer programs to
improve the readability of consent forms. The computer corrections gave little
improvement in readability scores but evaluations by volunteers rated the graphically
improved versions as easiest to comprehend.
The importance of format is similar to the importance o f readability. If the
consent form is a written document and because of print size or other problems with
format the inform ation is not easily understood it can interfèr w ith notential research
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subjects understanding the information they need to make an informed decision.
Comprehension
Comprehension is the measure o f the understanding o f the information potential
subjects have received A review of the literature on comprehension of informed consent
documents confirmed that research subjects do not have enough understanding of what
they read to make informed decisions. Miller, Searight and Grable (1994) conducted a
study of 168 patients enrolled in a clinical trial. A telephone survey was used to evaluate
recall of study information from the informed consent Most patients rated themselves as
well-informed about the study but were not able to recall important study information.
Fifty' patients participating in twenty-three different research protocols were
evaluated for understanding of the consent forms and only one-half were rated as
adequately informed (Schultz, Pardee & Ensinck 1999). A smdy, conducted in Veterans
Administration hospitals involving 156 research patients, revealed that of 40 consent
forms analyzed, a college-level education on the average was required for adequate
comprehension (Riecken & Ravich, 1982). McCormack, Evoy and Mulcahy (1997)
tested 50 patients who had consented to orthopedic procedures during their post
operative stays. Most of the patients showed limited understanding of the terminology
used in the consent forms they had signed, indicating they may have consented to
procedures they did not really understand. Waggoner and Mayo, (1995) and Waggoner
and Sherman (1996) conducted smdies to evaluate the understanding of 25 commonly
used words in clinical research consent forms. The first smdy involved 287 subjects, the
second 302 subjects. In both smdies, understanding o f the words was highly variable
with those silhiects who had higher eritirationc dnino hptter nuerall
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Problems with readability and format can prevent potential research subjects from
receiving important study information. Research on comprehension is important since it
has been shown that readability as the sole measure of patients’ comprehension o f
medical consent forms is not a sufficient measure of potential research subjects ability to
understand the information that is provided in the informed consent process (Mariner &
McArdle, 1985).
Subject Satisfaction
The literature also suggests a relationship between satisfaction with the research
study and the participant’s knowledge of the study. Research concerning subject
satisfaction with the consent process was found in only three studies. Tabak (1995)
interviewed 66 patients, most stated they did not have sufficient time to decide if they
wanted to participate, and a small majority responded they felt pressured to consent.
Verheggen, Jonkers and Kok (1996) interviewed 198 patients involved in clinical trails in
the Netherlands. Overall the patients reported being satisfied with both oral and written
consent procedures. Williams, French and White (1997) surveyed fifty-nine patients who
were asked to participate in a clinical trial and they stated they were satisfied with their
decision to participate.
Consent Process
Another variable that may influence how much of the consent form is read is the
process, specifically how the form is presented to a potential subject. Morrow, Gootnick
and Schmale (1978) did not determine how much of the form 77 subjects read, but did
report a higher comprehension in patients who took the form home to read prior to
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comprehension scores or level of satisfaction between two groups of out-patients who
either received a consent form 24 hours before the procedure and those who received it
immediately before the out-patient procedure (Neptune & Hopper 1996).
Patient Advocacv
A final factor that may influence the amount of the consent form that is read by
potential clinical research subjects is their degree of patient advocacy. Stress caused by
chronic or life-threatening illnesses can cause a “self-help” response (Brader, 1990) in
which patients are more likely to become “activists” or active agents (Thouts, 1994) in
managing their illness. Brashers and Klingle (1992) maintain that activists are more
involved in decisions about their health care. This involvement can be described as selfadvocacy. Self-advocacy behaviors are used to represent “one’s own interest in decision
making processes” and can result in a change in physician-patient interactions (Brashers,
Haas & Neidig, p. 99,1999).
Ballard-Reisch (1990) suggested a model of physician-patient interaction that
would be different fixjm the traditional encounter where the physician has the power over
the patient She purposed that physicians and patients share responsibilities for decisions
using open communication. Beisecker and Beisecker (1993) see this change in
communication style between physician and patient as a shift from a paternalistic to a
consumeristic model o f interaction. They also suggested that individuals following the
consumeiistic model desire more information from their health care provider.
Related to self-advocacy is the level of desire to participate in medical decision
making by patients. Strull, Lo, and Charles (1984), assessed patient’s preferences for
AAA ALAWVAAWXAA \A W W A O A \ /A A A A A U C X A A A g »
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than half of the patients requested more information about their disease. In this smdy it
was determined that clinicians overestimated their patients desire to be involved in
therapeutic decisions.
Robinson (1986) analyzed taped informed consent discussions with 644 patients
prior to cardiac surgery. Twenty-five percent o f the patients refused to hear part or all of
the informed consent information. Beisecker and Beisecker, (1990), Thompson, (1994),
and Waitzkin (1985) question whether patients are taking a more participative approach
in decision making about their health despite the fact that patients express a desire for
more infbrmatiotL Research by Hinckley, Craig and Anderson (1989) indicates that in
actual practice the majority of patients are not willing or able to take an active role in
health care decision making. Of the patients who do desire more information about
health care and participate more in the decision-making process about care Beisecker and
Beisecker (1993) saw a switch by these patients firom a paternalistic to a consumeristic
model of decision making. Braden (1990), described a “self-help” response to chronic or
life-threatening illnesses where patients were more likely to become “active agents”
related to their illness. Even though it is recommended that patients should become more
involved in health care decisions little research has been done to determine if patients are
or desire to be more active (Brashers & Klingle, 1992).

Summary

The extensive literature search of Medline, Cinahl and government Internet sites
found only a small number of studies addressing how much o f the informed consent
document is actually read by clinical research subjects. O f the studies that were found it
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can. be concluded that research subjects have limited understanding and comprehension
o f the study they are agreeing to participate in if they do not read the informed consent
document This also means they can not give true “informed” consent to participate.
These findings are supportive of a need for further study to better understand why
research subjects do or do not read consent material and how it may affect subject
satisfaction with the study as well as impacting study data.
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CHAPTERS

FRAMEWORK
This chapter presents the theoretical framework used in this study, research
questions, theoretical definitions, operational definitions and assumptions.
During the review of literature variables were identified that might influence how
much of the informed consent document is read by potential research subjects. The type
of relationship potential research subjects have with their health care providers has been
suggested as one of the variables that influence how much of the consent form is read.
Asymmetric or paternalistic interactions where the health care provider has the majority
of influence in the encounter is usually the most common type o f interaction (Guttman,
1993; Treichler, Frankel, Kramerae, Zoppi, & Beckman, 1984). However the relationship
can vary between the extremes of paternalism and consumerism (Gadow 1983).
The Existential Advocacy model proposed by Gadow (1983) was chosen as the
framework for this study because it stresses the principle of self-determination in patient
health care decisions while allowing for a variety of interaction types. Gadow proposes
that in “ any given encounter the patient and nurse can freely decide whether their
relationship shall be that of child-and-patient, client-and-counselor, friend-and-fiiend,
coUeague-and-coUeague, and so on through the range of possibilities” (p. 42). The type
o f relationship may determine how much information the potential subject wants to
icucivc.
17
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Theoretical Framework

Gadow defines existential advocacy as ' ^ e nurse’s assistance to individuals in
exercising their right o f self-detennination, through decisions which express the full and
unique complexity of their values” (1983, p.55). Informed consent can be defined as the
consent of an individual or his or legally authorized representative to participate in
research without undue inducements or any form of fraud, deceit duress, or other
constraint or coercion (Southwick, 1988; Bok, S. 1992). Government regulations
mandate what information must be presented to the potential research subject to enable
them to give informed consent. Legal obligations can be met by giving information to
potential research subjects in the form of a written document (Code of Federal
regulations. Title 21). However, the review o f literature has identified several variables
that can interfere with potential subjects receiving the information that they need to make
a truly informed consent. Gadow recognizes that there are a variety of interaction types
between health care providers and patients because each patient has “unique strengths
and complexity” (1983 p. 43).
Gadow states that the concept of existential advocacy is the “opposite of
paternalism”. She defines paternalistic acts as those which “limit the rights of
individuals in their own interests”(p.43). Another view o f paternalism is that it is
sometimes better for the patient if the person who makes the decisions is the one who is
most knowledgeable in the situation. The intent of informed consent is not met during a
paternalistic type interaction.
Although advocacy is opposite from paternalism it is not consumerism. Gadow

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

19
with “technical” assistance only, where information is given but no recommendations are
provided. Existential Advocacy’s goal is to “help persons become clear about what they
want to do” by being interested in the other’s good more than their own (Gadow p.4445).
The object of this study was to determine if subjects made informed consent
decisions to participate in clinical drug studies based on how much of the consent form
they read and their level o f self-advocacy. According to Gadow’s self-advocacy
framework the potential subject has varying needs at any given time concerning the
amount of help needed for informed decision making.

Research Questions
Research questions for this study were developed from Gadow’s theory of
Existential Advocacy (1983) and findings from the literature review.
1.

How much of the written consent form do clinical research subjects read?

2.

What is the relationship between how much o f the consent form clinical

research subjects read and self-advocacy?
3.

What is the relationship between how much clinical research subjects read

and the variables of sex, age, ethic group, gender, marital status, educational status and
occupation?
4.

What reasons do clinical research subjects give for reading or not reading

the informed consent document?
5.

Do clinical research subjects who read all or nearly all o f the consent form

have different reasons for participating in clinical research trials than those who indicate
tKat

ncttycant

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

20
Definitions

Informed consent is the intentional autonomous authorization, with substantial
understanding and lack of substantial control by others (Beauchamp & Childress,1994).
Informed consent was operationalized in the clinical drug studies as the process of
receiving, reading, and signing the study information (Beauchamp & Childress, 1994). It
was fulfilled if a research subject received a consent document that had been approved by
an institutional review board after fulfilling all government and or local regulations. A
wimessed signature on the informed consent was necessary, but no requirement to verify
that the consent was read, or was understood.
Existential advocacv is a process that involves the nurse and the patient deciding
what the relationship will be in health care encounters (Gadow, 1983). The patient and
health care provider’s relationship can vary from paternalism to consumerism (Brashers,
Haas &Neidig, 1999). Existential advocacy was operationalized by the summed score
from the participants responses on the Patient Self-Advocacy Scale which measured the
level of self-advocacy on a continuum from paternalism (not an advocate) to
consumerism (active self-advocacy).
Clinical research subject is an individual participating, or who has participated in
a pharmaceutical drug study.
Readabilitv is the reading grade level required to understand an informed consent
document.
Format is the way the consent form is arranged including type size, order,
spacing, font and style, measured by question two in the demographic data form.
uinpiciicuaiuix w uuuvtdumumg u i uiivtiuauvu picacutcu ui ou luiviiucu
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consent document, measured by question three in the demographic data form.
Subject satisfaction is whether or not clinical research subjects received the
amount o f information about a study that they desired, measured by question seven on
the demographic data fonn.

Assumptions
Study participants will honestly answer questions regarding how much of the
consent form they read and why or why not

Summarv
Existential Advocacy was chosen as the framework for this research study
because it stresses the principle of self-determination in patient health care decisions.
Research subjects have the right to know what they are getting into and the right to say
no for good reasons, bad reasons or no reason and the consent process has been
developed to insure that this right to make an independent decision is honored.
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CHAPTER 4

METHODOLOGY
This chapter describes how the study was conducted. The subsections covered
include study design, population, sample, setting, procedure, tools, statistics, and human
subject rights.

Design
A comparative descriptive design that examines and describes “differences in
variables in two or more groups that occur naturally in a setting”, was used (Bums &
Grove, 1997). The design was used to examine and describe differences in variables
between those subjects who read all of the consent form and those who did not read all of
the consent form.

Population
The target population was any person age 50 to 75, who signed an informed
consent document and agreed to participate in a clinical research trial for a
pharmaceutical company. Excluded groups were vulnerable populations, cancer and HIV
trial participants. The accessible population was people who had signed an informed
consent document within the previous year and agreed to participate in a clinical research

22
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trial, were still participating in the research trial and were being seen at one o f the three
research centers where data were collected.

Sampling
Convenience sampling was used to identify the first one hundred usable responses
by people in the before mentioned groups who volunteered to be part of this study.

Setting
The sample was obtained from three privately owned for profit research centers
located in Ohio and Nevada. The three sites were similar in size, subject population, had
a single investigator and two research coordinators. Persons asked to participate in this
research study were subjects enrolled in the same clinical drug trials and who had the
same informed consent documents.

Procedure
Research subjects who where currently taking part in a clinical drug trial were
approached after all visit procedures were completed when they came to one of the
centers for their regularly scheduled appointment The purpose of this study was
explained to the subject by a research coordinator who was trained by the principal
investigator. The same procedure was followed at each site. If the person expressed
interest in participating in this study they were given a consent document to read. If the
subject consented to participate they signed the informed consent. Next the subjects
w<*n» crivpn twn ni«»ctifinnnirpc tn
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the demographic data form (DDF) and the second questionnaire was The Patient SelfAdvocacy Scale (PSAS). After completing both items the subject was asked to place the
questionnaires in a plain envelope and seal i t The envelopes were stored in a locked
cabinet until they were mailed or delivered to the principal investigator. After it was
verified that the consent form had been signed the questionnaires were separated from the
consents to maintain patient confidentiality. The data were transferred to a computer
spread sheet The completed questionnaires and Patient Self-Advocacy Scales will be
destroyed after a minimum of three years.

Tools
Data were collected using two tools. The first tool was the Demographic Data
Form (DDF), found in appendix A. This form was developed by the researcher and
reviewed by two expert nurses for clarity and conciseness after which modifications
suggested by these nurses were made. The purpose of the DDF was to obtain basic
demographic information about the sample such as age, marital status, educational level,
and gender. These questions were identified as possible infiuencing factors based on the
Strull (1984) study in which a correlation was found between degree of decision making
and gender, age, race and education level. In addition to the previous questions subjects
were also asked how much of the clinical trial consent form they had read and why.
Three hems, questions 3 ,4 and 5, dealt with the subjects’ subjective opinion o f their
comprehension of the consent form and possible variables that may have interfered with
comprehensioiL Item 6 on the form asked for reasons the subjects had for participating
V lA W V l A i X l V O k V U U g
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The second tool used was the Patient Self-Advocacy Scale (PSAS), (Brashers,
Haas & Neidig, 1999). Patient Self-Advocacy was identified as a possible variable
influencing the amount of the clinical trial consent form subjects read. The PSAS was
used to measure patient involvement in health care decision making and scores of
possible low of 18 reflecting low self-advocacy or paternalism to a possible high o f 90
for self-advocacy (Brashers, Haas & Neidig 1999). The PSAS was developed because of
some questions raised in a 1984 research study concerning shared decision making by
patients and clinicians. Strull, Lo and Charles (1984), found that although shared
decision making had been identified, little was actually known about how much decision
making patients actually prefer. The PSAS was chosen as a tool because of the
framework selected for this study, existential advocacy. Gadow (1983) states that at any
given time the potential subject has varying needs concerning the amount o f help they
want with health care decision making, an opinion shared by Ingelfinger (1980).
The Patient Self-Advocacy Scale is an 18 item questionnaire answered in a 5point Likert format ( Brashers, Haas & Neidig 1999). To test the validity o f the PSAS
the authors used several other measures. Discriminent Validity was evaluated by the
Desire for Control Scale (Burger, 1992), Health Opinion Survey Instrument (Krantz,
Baum & Wideman 1980), Desire for Autonomy Scale (Ende, Kazis, Ash & Moskowitz
1989), and Health Locus of Control Scale (Dahnke, Garlick & Kazoleas, 1994). A
combined sample of 392 subjects was used to evaluate the tool, 174 adults from an HIVAIDS population and 218 adults from a general population. Conclusions by Brashers,
Haas, and Neidig (1999), were that “this was a reliable and valid means for measuring
patient mVulvcmcnt in health care ucCiSiOü making and ihai measuring seir-advocacy is
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important because it may be associated with increased health care participation” (p. 113 ).
To assess efiBcacy of the measurement tools for this study a pilot study was
conducted consisting of 5 individuals age 50 to 75 who had previously participated in a
clinical drug study. They were asked to review the questionnaires and make suggestions
regarding readability, comprehension and format. The pilot group requested changes in
font size (larger), and terminology. Specifically they suggested referring to the studies
they had participated in as “drug” studies. Changes were made to the questionnaires
following their suggestions.

.Analvses
Nominal and ordinal data were collected for this smdy. Both descriptive and
inferential statistics were used to analyze the data and because of the data collected
nonparametric tests were used. The SPSS computer program used descriptive statistics
including measures of central tendencv' and measures o f distribution to describe the
sample obtained.
Research question number one. How much of the written consent form do
research subjects read? was answered by question one on the DDF. Research question
two. What is the relationship between how much of the consent form clinical subjects
read and self-advocacy? was answered by obtaining the PSAS total summed score of
items and then looking for a relationship between PSAS scores and the amount o f the
informed consent that was read. Research question three. What is the relationship
between how much clinical research subjects read and the variables o f gender, age, ethic
group, marital status, educational status and cccupaticn? was answered by items 10
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through 15 on the DDF and item one on the DDF. Research question four. What reasons
do clinical research subjects give for reading or not reading the informed consent
document? was answered by the second part of question 1 and question 2 on the DDF.
Research question 5, Do research subjects who read all or nearly all of the consent form
have different reasons for participating in clinical research trials than those who indicate
they read little or none of the consent form? was answered by question 6 on the DDF.

Human Subjects Rights
Human subjects rights approval was obtained form the Department of Nursing
and the Human Subjects Rights Committees at the University o f Nevada, Las Vegas, (see
Appendix A). Prior to participation in this study all subjects were given an informed
consent document to read that explained the purpose of the study, potential risks, possible
benefits, and that their participation was voluntary (Appendix B). Participants were told
that they could withdraw at any time without penalty and without affecting their
participation in the drug study. Subjects who agreed to participate received a signed
copy of the consent document. No minors or vulnerable populations, including cancer
patients, intellectually impaired, HIV positive, nursing home residents, or non-English
speaking patients were included. .All data were kept in a locked cabinet, and only
numbers were used on the questionnaires for identification. Data were accessible only to
the study personnel. There was no direct benefit to the subjects of participation in this
study, but the results may benefit future clinical research participants. No risks related to
participation in the research study were identified, the risk-benefit ratio was neutral, and
nnlv r*nct trv maTtînîmamfc woe tho "XCi fr%
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CHAPTERS

RESULTS
This chapter discusses the findings o f this study. Included is a description of
sample and setting, the data analysis procedures and the results obtained from these
analyses.
Sample
The target population for this study was any person age 50 to 75 who had signed
an informed consent document and agreed to participate in a clinical research trial for a
pharmaceutical company. One hundred and five subjects at three research centers agreed
to participate in the study and returned informed consents, demographic data sheets and
Patient Self-Advocacy Scales. Sites one and two were located in Las Vegas, site number
three was located in Ohio. Site number one had forty-two participants, site number two
had twenty-two participants and site number three had thirty-seven participants.
Participants at all three sites were reflective of the people recruited into the clinical
research trials showing no significant differences demogr^hically in regards to age,
gender, education, marital status, race or occupation. All three sites were conducting the
same research studies in therapeutic areas for hypertension, arthritis, female incontinence
and diabetes. Although all the subjects suffer from chronic conditions none were lifethreatening at the time of the study. These clinical research trials were testing drugs that
uwk /wi. uwwix
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to participants in clinical research trials. Consent forms for the clinical drug studies the
subjects were participating in were evaluated using the Flesch Readability Formula
(Grundner, 1986) and had readability scores ranging from grade 10.3 to grade 12.
Eight subjects were initially excluded from the study. Four subjects did not meet
the inclusion criteria for age. Four subjects were excluded from the study due to
incomplete questionnaires. After reviewing the data from the eight excluded subjects the
four originally removed due to age were returned to the sample when it was determined
that they were age 75 when they originally had entered into the clinical research studies
giving a total of 101 participants.
Demographics
The characteristics of the sample population were obtained through the use of the
Demographic Data Form. The ages ranged from 50 to 76 years, with a mean age of 62.90.
Descriptive statistics were used to organize the data regarding, gender, marital status,
educational status, occupation and ethnic group ( see Table 1). O f the total participants
78 (77.2%) had never been in a clinical drug study before, 23 (22.8%) had previously
been in a clinical drug study. A crosstabulation was done to determine if there was any
difference between those vdio had been in a study before and those who had not in relation
to the amount of consent read. The analysis showed that of the 78 who had not been in a
study before 78.2% read all the consent, and of the 23 who had been in a study before
73.0% read all the consent. The conclusion was that there was no difference between the
two groups due to previous study participation in relation to the amount of the consent
form that was read.
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Research Questions
Research Question Number One
How much o f the written consent form do research subjects read? This question
was answered with data from question one on the Demographic Data Form. Seventy-eight
(77.2%) of the one hundred and one participants answered that they read all o f the consent
form. Nineteen (18.8%) of the participants said they read most of it (% to %), three
(3.0%) responded that they read some (% to ‘A) and one (1.0%) read a little (%). No one
responded that they read none of the consent form.
Research Question Number Two
What is the relationship between how much o f the consent form clinical subjects
read and self -advocacy? The relationship between how much of the consent was read and
self-advocacy was answered by first obtaining the total summed score of the eighteen
items on the Patient Self-Advocacy Scale (PSAS). Question number 2 also asked
participates how much o f the consent form they understood (see table 6). Brashers (1999)
study showed that the PSAS was able to discriminate between self-reported activist and
nonactivist participants. The possible scores on this form range from eighteen to ninety
with a score o f ninety representing the highest level o f self-advocacy. The sample’s
scores ranged from a low of 42 to a high o f 82. The mean score was 62.67 (SD = 6.68).
Because of the small number (4) of subjects who responded that they had read less than
most of the consent form it was decided that data firom this question would be recoded to
two groups. One group represented those who read all o f the consent form and the other
group was those participants who read less than all o f the consent form. The seventyp ta h t narticinanTc tvtm

all n f th«» rr»n«#>nt fWrm haH a m gan cr-nm

fiX n n th*» PÇA S

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

31

and a standard deviation of 6.31. The twenty-three participants who read less than all of
the consent form had a mean score of 61.57 with a standard deviation of 7.85 on the
PSAS. Anova results for read versus not read on self-advocacy was F= 0.94, (df 28,72),
P=.55 (see table 2).
This finding supports the position there is no relationship between PSAS scores
and amount of informed consent read.
Research Question Three
What is the relationship between how much of the consent form clinical research
subjects read and the variables of age, ethic group, gender, marital status, educational
background and occupation ? As in the previous question participants response to how
much of the consent form did you read was recoded to those who read all o f the consent
form and those who read less than all of the consent form. Crosstabulations were done
comparing all the above variables and read all the consent form or did not read all the
consent form. No significant differences were found regarding age, gender, ethnic group,
marital status or educational background. The variable of occupation had six categories
casino, clerical, construction, homemaker, professional and retired. Of the six only one
category showed a significant difference, and that was construction where 75% did not
read all of the consent while 25% did read all the consent, however, this group only had
four members so it is not possible to conclude that construction workers in general do not
read all of a consent form. The conclusion is that the amount o f the consent form read by
this sample was not related to the variables o f age, gender, marital status, occupation,
ethnic group, or educational background. See table 3 for details.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

32
Research Question Four
What reasons do clinical research subjects give for reading or not reading the
informed consent document? This group was recorded to those participants who read all
the consent form or did not read all the consent form. This question was answered on the
DDF as an optional part to question number one. Subjects were instructed to select one or
more answers if they did not read the entire consent form. One subject who reported not
reading the entire form did not answer this question so there is no data as to why her/she
did not read the entire consent form. One subject who read the entire consent form
answered yes to the choice that “someone in the research department explained the drug
smdy to me so I ^ d n ’t think I needed to read the entire consent form”. O f the participants
who did not read the entire consent form fifteen (652%) responded that “someone in the
research department explained the drug smdy to me so 1 didn’t think I needed to read the
entire consent form”. Four (17.4%) o f the group who did not read all o f the consent
responded that “my doctor suggested I take part in the drug smdy and I trust his/her
judgment so 1 didn’t read the entire consent form”. Two (8.7%) of the respondents who
did not read the entire consent said “a fiiend or family member read the consent form and
explained it to me so I didn’t read the entire form”. One (4.3%) participant responded,
“got information from a source other than the consent form” and two (8.7%) responded,
“I wasn’t in the mood to read the entire drug smdy consent form”. Seven (30.4%)
answered “other”, for the reason they did not read the entire consent form. Only three
who answered other wrote in a reason for not reading the entire consent One fifty-four
year old female wrote in that she did not read the part pertaining to females of
childbearing age. A fi^'-tv/o year old male who answered that he read some o f the
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consent (1/4 to 1/2) and that someone in the research department explained the drug study
to him wrote in that he “read the first form completely”. It is not known what he was
referring to as none of the studies these participants were in had more than one consent
form. The last “other” wrote in “bad eyesight” and also answered that a fiiend or family
member read the consent form and explained it to me so I didn’t read the entire consent.
Based on the data collected the conclusion is that those who did not read the entire
consent form got the information from another source, most often from someone in the
research department.
Research Question Number Five
Do clinical research subjects who read all or nearly all o f the consent form have
different reasons for participating in clinical research trials than those who indicate that
they read little or none of the consent form? Data to answer this question were obtained
from question one on the DDF and question six on the DDF. Participants had the option
of choosing more than one answer for the reason they entered a drug study. The data
regarding the amount of consent form read were again collapsed into two groups, those
who read all of the consent and those who did not read all of the consent.
Crosstabulations were done to determine if there was any significant difference in
the reasons participants gave for agreeing to be in a drug study wiio read all the consent
form and participants v6o did not read all the consent form. Of the 19 who responded the
study gave them a chance to get medical care they could not afford 6 (31.6%) did not read
the entire consent. O f the 17 who responded that they entered the study because it paid
money 6 (35%) did not read the entire consent. O f the studies that the sample was drawn
from only one study bad a patient stipend for participation. O f the forty-eight who
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responded they had tried every other treatment and it had not helped, 13 (27%) did not
read all the consent form. The most frequent reason given for participating was that it
was an opportunity to obtain medication not otherwise available 59 (58%). The answer
“I ’ve tried every other treatment or medicine and nothing else has helped was selected by
48 (47.5%) of the participants. A crosstabulation showed 70.8% of the participants that
choose the opportunity to obtain medicine also choose no other treatment or medicine has
helped. Participants who entered the clinical studies for money or to obtain medical care
were less likely to read the entire consent form than those who entered the studies for
other reasons. See details in Table 3.
Additional information was obtained from the DDF. (Question number 2 and 4
asked general information about the consent form relating to readability. The results are
in Table 4. Question three on the DDF asked how much of the consent form did you
understand. Table 5 summarizes how much the participants understood and how much of
the consent they read. It should be noted that the amount of consent form understood was
not validated with an actual check of the participants knowledge of the study.
Not all the subjects who participated in the study had the same consent form for
their drug study. No data were collected regarding which form they read. There were a
total of four different consents that were created by four different pharmaceutical
companies. All the consents were similar in length and reading grade level 10 to 12. The
general information in the consents was the same as mandated by FDA guidelines.
Of the total participants 78.3% percent o f those who did not read the entire
consent and 89.7% o f those who did read all answered that they received all the
information that they wanted fix)m the consent However. 73.9% of those who did not
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read all the consent, and 83.3 % o f those who did read all the consent said they asked
questions before they signed the consent form. Another question asked the participants if
they would be in a drug study again. Of those who did not read the entire consent. 87%
responded that they would be in another study, 8.7% might be in another study, and 4.3%
would not be in another study. O f the participants who read the entire consent form
74.4% would be in another study, 21.8% might be in another study, and 3.8% would not
go in another study.
Summarv
The answer to research question one, how much of the written consent form do
research subjects read, is that of the 101 participants 77.2% said they read all o f i t
Question number two, asked what is the relationship between how much o f the consent
form clinical research subjects read and scores on the PSAS (self-advocacy). In this
sample there was no difference in PSAS scores whether the participant read all or less
than all of the consent form. Question number three, what is the relationship between how
much of the consent form is read and the variables of age, ethnic group, gender, marital
status, educational background and occupation.? Only one variable showed a relationship,
with those in construction reading less of the consent than those in other occupations or
retired. However there were only 4 members in this group so it is not possible to
generalize this finding to construction workers in general. What reasons do clinical
research subjects give for reading or not reading all the consent form was research
question number four. Since this was an optional items on the DOF not all participants
responded.
O f those who did answer the most frequently chosen reason for not reading the
entire consent was that they received information from someone in the research
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department, perhaps leading them to believe it was not necessary to read the consent. The
final research question was did research subjects who read all of the consent form have
different reasons for participating in the research study than those who did not read all the
consent form. More than a third o f those who were in a clinical research study because it
paid money, or they received medical care they could not otherwise receive, did not read
all o f the consent form.
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CHAPTER 6

DISCUSSION

The purpose of this descriptive study was to answer questions related to the
informed consent process in clinical drug studies, specifically how much o f the informed
consent document is read and variables related to how much is read. This chapter
discusses the major findings in relation to the research questions, study framework and
previous research. Limitations that were identified are discussed as well as implications
for nursing and recommendations for further research.
Research Questions
How much of the written consent form do clinical research subjects read? O f the
one hundred and one participants wiio responded to this question seventy-eight (772%)
answered that they read all of the consent These results contradict previous reports that
research subjects read less than fifty percent o f a written consent (New York Times,May
1999). This is also in contrast to the researcher’s personal observations that research
subjects do not read all of the consent form and FDA audits of research sites from 1977 to
1984 that cite the most violations o f FDA regulations to be in the area o f informed consent
(www.fda.gov/cder). Possible explanations for these findings may be that the participants
observed by the researcher were not typical, participants may pretend to read the consent
form (Tenthory & Dixon, 1996) and that the FDA audits may reflect problems with the
CCnSCuuIig OuIcT uîS ü th e cuHGuut o f t h e dOCUmcut th a t iS £câd*
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The answer to the second research question, what is the relationship between how
much of the consent form clinical research subjects read and self-advocacy was that no
relationship was found. There was no significant difference in self-advocacy scores
whether the participant read all, most, or some o f the consent The mean PSAS was 62.67
with a standard deviation of 6.68. Two o f the participants with the lowest scores on the
PSAS, 42 and 49 reported reading most of the consent form. The third participant who
scored 51 on the PSAS reported reading all of the consent form. A possible explanation
for this finding may be that research subjects as a group may be more assertive in regards
to health care than individuals who do not participate in clinical research studies. In
addition, this sample may not be representative of the average research subject. During
the literature search no studies were found that addressed this issue, so this remains an
area that needs further research.
The third research question asked, what is the relationship between how much
clinical research subjects read and the variables o f sex, age, ethic group, gender, marital
status, educational status and occupation. Because of the small number of subjects who
read less than most of the consent the four groups were collapsed into two groups, those
who read all the consent and those who read less than all the consent No statistical
differences were found regarding the above variables regardless o f the amount of consent
that was read. Additionally no statistical differences were found on PSAS scores, the
amount of the consent that was understood or the reasons for participating in a clinical
study regarding the variables of sex, age, ethic group, gender, marital status, educational
status or occupatioiL A possible explanation for these findings may be the homogeneous
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nature of the participant sample. The majority of subjects were retired, married
Caucasians, with some college education. About two-thirds were female.
Research question number four, what reasons do clinical research subjects give for
reading or not reading the informed consent document? The results from this question are
inconclusive possibly because of the way the question was asked on the demographic
data form. It was an optional part to the question that asked how much o f the consent was
read. It said that if you did not read the entire consent form check all the answers that
apply. Since 77.2% of the participants answered that they read all of the consent form
limited data were obtained. However 652 % of those who answered that they did not read
the entire consent said that the reason was because someone in the research department
explained the drug study to them. This was actually only fifteen participants in the smdy,
but is valid because all fifteen also said that they asked questions about the smdy before
they signed the consent However, IRB’s give approval based on the written material not
that the researcher will provide oral information to all of the potential research subjects
reading the form. O f concern is the possibility that information will not be provided
because o f a conflict of interest due to that fact that investigators in clinical drug smdies
usually receive payment based on the number of subjects who agree to participate in a
smdy.
Do clinical research subjects who read all or nearly all of the consent form have
different reasons for participating in clinical research trials than those who indicate that
they read little or none of the consent form was the final research questioiL Again the
respondents were collapsed into two groups, those who read all the consent and those who
read less than all the consent Slishtlv more than 30% o f those who entered clinical trials
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for money or because they could not afford to get medical care elsewhere did not read the
entire consent form. This finding is bothersome because they may in fact represent a
vulnerable population, the poor or uninsured and may not be giving true informed consent
A second group, those who have tried every other treatment or medication with no success
and are now seeking medication that is not available except in clinical trials are also
vulnerable. Although the majority of this group did respond that they read all o f the
consent, is their desire for relief influencing their decision to participate to a point where
they may be willing to take risks that another individual who felt they had other options
might not take. Also, at risk subjects consent forms do not differ firom not at risk subjects
in relation to IRB approvals.
Studv Framework
The framework for this study was existential advocacy. The goal o f existential
advocacy is to “help persons become clear about what they want to do” stressing selfdetermination in health care decisions (Gadow pp. 44-45). The PSAS was used to identify
the participant’s degree of self-advocacy. The scores of this group on the PSAS reflect
their high level of involvement in health care decision making. This sample showed their
involvement by reading most or all of the consent form, and responding they understood
most or all of the consent form and that they received all or most of the information they
desired. Additionally, 812% of the participants answered that they asked questions
before signing the consent. Verheggen, Jonkers & Kok (1996) interviewed 198 patients in
clinical trials and found that overall they were satisfied with informed consent. He found
that this satis&ction was influenced by attitudes toward medical care, research and trust
in their physicians. O f the participants in this study 49.5% answered that one o f the
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reasons they went into the study was because their doctor said it would be a good idea
reflecting their trust in their physicians. If Gadow ( 1983) is correct this would be also be
an example o f the physician acting in the interest of the patient’s good. However it is
unknown what the physician’s motivation is, it may be the patient’s best interest, or it may
also benefit the physician if he is being paid for conducting the clinical trial. In addition,
this study did not identify if the research subject was made aware of the latter fact
Previous Research
The results of this study appear to contradict other previous research in addition to
those studies dealing with the amount of consent foim read. In comprehension studies,
Riecken and Ravich, (1982) and Miller, Searight and Grable, (1994) concluded that
subjects do not have an adequate understanding o f the informed consent documents yet
62.4% of the participants in this study reported they understand all o f the consent, while
30.8% understood most o f the consent, and 4.0% understood some of the consent form. A
limitation with this study is that there was no objective test of participants understanding
o f the consent form information. Their response was a subjective opinion o f what their
level of understanding was.
Implications for Nursing
Evidence in case law documents show health care professionals are legally liable
for adverse outcomes by patients who do not understand important health information
(Brandes, Fumas, McCllan, Haywood, Oheme-Frempong, & Taylor-Watson, 1996).
Also, if a nurse, in lieu o f a physician, explains a medical or surgical intervention to gain a
patient’s informed consent they can be held to the same standard as court would hold a
physician (Curran, 1982). The signature of a low health-literacy patient on a consent form
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may not indicate informed consent (Cassileth, Zupkis, Sutton-Smith & Morch, 1980).
The legal validity o f the consent may be questionable even if the patients have read the
form if there is incomplete comprehension of the material (Powers, 1987). Patients with
poor health literacy that prevents their comprehension of the informed consent may also
have problems understanding and following instructions concerning the clinical study they
are participating in leading to poor compliance with the study requirements ( Spandorfer,
Karras, Hughes & C ^uto, 1995). In addition such may also limit their reporting of
serious events that may have an impact on approval of the drug by the FDA. If serious
events are not reported and approval is given open public use may result in injury or even
death due to lack of fiill and accurate reporting in the clinical trial.
Limitations
This study was limited to three research sites that were extremely similar as far as
patient population and method of obtaining informed consent The participants were for
the most part patients of the physicians conducting the clinical drug study and had some
type of patient/ health care provider relationship with the research staff. At these sites
R.N's are consenting the patients and this may not be the norm for all research centers.
Additionally this was not a diverse group in many areas such as age, race, education or
occupation. There were problems identified with the DDF. Information was lost by
making some answers dependent on the answer to the previous question. No general
conclusions can be drawn fi'om this study.
No information was obtained as to what type o f research study the participants
were taking part in. For example some participants were in a hypertensive study where
numerous alternative medications are available to the public. Therefore it was not
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necessary for them to participate in a clinical study to obtain medication for their medical
condition. However the females participating in the urge incontinence study did not have
the same number of alternatives available as those in the hypertension study. There are
no medications currently available that are comparable to the one that was being test in the
clinical trial. These differences may cloud some of the data.
The PSAS, which was used to test patient self-advocacy, had not previously been
used on clinical research subjects. Because o f what appeared to be some contractions in
responses to questions regarding why the participants went into the study and high scores
on the PSAS (my doctor suggested 1 enter the study), it might be that the tool is not
discriminating enough for this group.
Conclusions
The results from this study cannot be generalized to all clinical research subjects.
Results would indicate that this sample which was mostly retired, married, female,
Caucasians with some college read and understood most o f the consent form. They
thought the form was boring but they received all the information they wanted. This
groups main motivation for entering a clinical study was to get medication that is not yet
otherwise available, and they also though it might help other people. Additional reasons
for participation that were frequently chosen were that it would be interesting, their doctor
thought it would be a good idea, and no other treatments were working.
Recommendations for Further Research
Based on the overall findings in this study the following recommendations are
made.
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1.

Check the participants understanding o f the consent form by asking a few

pertinent questions about the consent after it has been signed. For example ask the
participant to name two potential drug side effects, how many visits will be required and
who to contact in an emergency.
2.

Obtain the sample from a more diverse number of sites, such as for profit,

non-profit, university based and centers that obtain research subjects through
advertisements only
3.

Obtain the sample finm sites where the consent process is conducted by

nurses and non-licensed research coordinators.
4.

Obtain a more varied sample in regards to age, race, education and reason

for participation such as patient payment.
5.

Have the subjects take a health literacy test such as the Rapid Estimate of

Adult Literacy in Medicine (REALM) which can identify patients with low reading levels
in relation to health terminology ( Davis, Long, Jackson, Mayeaux, George, Murphy &
Crouch 1993).
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Table 1 Participant Demographics

( N=1 Oil

Age Range 50-76 Mean= 62.90

Gender
Male
Female

Freauencv
37
64

Percent
36.6
63.4

Marital Status
Single
Married
Divorced
Widowed

Frequencv
15
56
12
18

Percent
14.9
55.4
11.9
17.8

Highest Education
Less than high school
High school
Some college
College degree
Some graduate study
Graduate degree
Technical training

Freauencv
4
24
43
16
5
4
5

Percent
4.0
23.8
42.6
15.8
5.0
4.0
5.0

Ethnic Group
African
American Indian
Caucasian
Hispanic
Other

Frequencv
5
4
87
3
2

Percent
5.0
4.0
86.1
3.0
2.0

Occupation
Casino
Clerical
Construction
Homemaker
Professional
Retired
Sales
Service
Technicians
Other

Frequencv
3
8
4
8
13
41
4
3
12
5

Percent
3.0
7.9
4.0
7.9
12.9
40.6
4.0
3.0
11.9
5.0
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Table 2 ANOVA Results for Read vs. Not Read on Self-Advocacv
Sum of
Squares

Between Groups
Within Groups
Total

4.771
12.991
17.762

df

Mean
Square

F

28
72
100

.170
.180

.944

Sig.

.553
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Table 3 Crosstabulations Between Variables of Age. Ethnic Group. Gender. Marital
Status. Educational Background. Occupation and Amount o f Consent Form Read

Occupation

Did not read all o f consent

Read all of consent form

Casino
% within occupation

0

3
100%

Clerical
% within occupation

2
25%

6
75%

Construction
% within occupation

3
75%

1
25%

Homemaker
% within occupation

2
25%

6
75%

Professional
% within occupation

3
23.1%

10
76.9%

Retired
% within occupation

6
14.6%

35
85.4%

Gender

Did not read all of consent

Read all of consent form

Male
% within gender

7
18.9%

30
81.1%

Female
% within gender

16
25%

48
75%

Marital Status

Did not read all of consent

Read all of consent form

Single
% within marital status

4
26.7%

11
73J%

Married
% within marital status

14
25%

42
75%

Divorced
% within marital status

1
8.3%

11
91.7%
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Table 3 (continued)
Widowed
% within marital status
Education

14
77.8%

4
222%

Did not read all of consent

Read all o f consent form

Less than High School
% within education

1
25%

3
75%

High School
% within education

9
37.5%

15
62.5%

Technical Training
% within education

1
20%

4
80%

Some College
% within education

8
18.6%

35
814%

College Degree
% within education

3
18.8%

13
81.3%

Some Graduate Study
% within education

1
20%

4
80%

Graduate Degree
% within education

0
0

4
100%

Ethnic Group

Did not read all of consent

Read all o f consent form

African American
% within ethnic group

1
20%

4
80%

American Indian
% within ethnic group

0

4
100%

Caucasian
% within ethnic group

20
23%

67
77%

Hispanic
% within ethnic group

1
333%

2
66.7%

Other
% within ethnic group

1
50%

1
509o
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Table 4 Cosstabulations Between Participants Reasons for Agreeing to be in a Clinical
Drug Study and How Much of the Informed Consent they Read

Reason for Participation
Gave me a chance to get
medication not available

Frequencv Did not read all consent Read all of Consent
59
10(16.9%)
49(83.1%)

I thought it might help
other people

58

13 (22.4%)

45(77.6%)

I thought it would be
interesting

57

13 (22.8%)

44 ( 77.2%)

My doctor said it would
be a good idea

50

9(18%)

41(82%)

13(27%)

35(73%)

I’ve tried every other
treatment nothing works

48

Family said it was a
good idea to enter study

29

7 (24%)

22 (76%)

Other reasons

22

7(32%)

15(68%)

Chance to get medical
care

19

6(32% )

13(68%)

Study pays money

17

6 ( 35%)

11 ( 65%)

I did not want to go
against my Dr. or nurses
recommendation

4

1 ( 25%)

3 (75%)
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Table 5 Crosstabulation Readability Questions About the Consent Form and Read or Did
Not Read All of The Consent Form

Readability o f Consent Form

Did not read all

Read all

The consent was too long

7

11

The type in the consent
was difficult to read

3

0

Did not have enough time
to read the entire consent

3

4

I felt rushed to read the
consent form

2

2

The consent form was
boring

10

20

The consent form was
clear

17

61

I received all the
information I wanted

18

70
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Table 6 Crosstabulation Between How Much o f the Consent Form Did You Understand
and How Much of the Consent Form Did You Read

Did Not Read All o f Consent

Read All of The Consent

Understood Some
(% tol6)
3.5% total sample

1%

3%

Understood Most
(>/2 to %)
33.5% total sample

10%

23.5%

12%

50.5%

23%

78%

Understood All
63% total sample
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Franc dboahai@uiue.edu (dak braahera)
Ta*JffiLV@aôixam
F3e Unknown (11160 bytes)
DLTime (2B800 bps): < 1 minue
Jcorme Iwouldbe happy tryaulouse1hepatiantsaifad«cacy scale
in ycurlhesis. I «mid appweiate.hearing ih e lesiits of ynrstudy
« ite n a e ia b e
We haw two otherpubficaiians in ttK «mks-one is thebackgraund far the
scale (n press at Hunan Consnunicatian Researah) and one that vnDsoon
be submitted. Also, the scale is being used in sewial other studies,
indudng
astudy of HIVvadnes being condused.by the CDC.
W ealsoaretestrganexpandeifveaianafthePSAS. Fram ouras& so
# it has better leliabiBytr the si±scales. but complete wOdabon
andiefiataiityinfatmation isnotavBiiatile. rm attaching a copy otthe
expanded PSAS.
Please let me know if 1can be of father assistance.
Dale '

>DearMc Biashec My name is J o a m Rofamson and hn pusuing amasterdgree
>in nusing at the Unheisity cf Neiada at Las Vegas. I recently read your
>anicle'The Patient SelM tecaq^ Scale: tMaasuing Pabentknolvement in
>Heallh CareDecisicmMaldng Wareetions' I «mid ike to use the PSAS in my
>mastere thesis. Ihe pnmaiy pupose of my thess is to d etem m ho«r much of
>the ndbmwd consent document eSnical researah sufajacts read, and whether
>ihere is a eonelation between how much cfthedoeunentisreadandwhat
>degree of lesponsMBty researah subjects take «iren making heakh care
>decsions. Iwoiidappreoaee any assistance you could give me regaidng
>obCaining infamatian about the PSAS and pemnssion to use it
>1hm*you, lean be reached at my home e m a i JHRLVQaoLcom oice«m aS
>NCRLV@aoLeomarofice«mknunber Mevada CSrial Researah 702471-7288
>

>My thesis chair is Or. Maigaret Lois University of Neoda Las Vegas
>Depamment of Nusing 702-89^3812

.Headers.
ReturePretc <*rasheiQuuc.ede>
Received torn ity-zc05.nstaoLcom @ty-zc05.m«iLaolan [17231Æ.g) by M cO Sunalaolcom (v7020) vath ESMTP:
Mon, 10 Apr 2 0 n 17:12:13 2000
Racanara i o n staC.cso.uuc:adu #tÂ.cso.uucLadu [128.174X6^ by ity-edfim.aaLeont (/Tt.lO) aiiir ESUTP; Mon;
10 Apr200017^1:43-0400
Recarvad: tiom [128.174.167^^ («alt1.speoniiuiue.adu [128.174.167JS{)
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DATE;

Sqjtember 26,2000

TO;

FROM;

Joanne Robinson
Nursing
Ml'S 3018
> ^ ,D r. William E. Schulze, D ir e c to r ^
L OfSce o f Sponsored Programs (xl357)

RE;

Status o f Human Subject Protocol Entitled;
“Variables Related to How Much of the Informed Consent Document is Read by
Clinical Research Subjects”
OS? #50ls0900-089

This memorandum is ofEcial notification that the protocol for the project referenced above has
been ^jproved by the Office o f Sponsored Programs. The approval is for a period o f one year
fiom the date o f this notification and work on die project may proceed.
Should the use o f human subjects described in this protocol continue beyond a year fiom the
date of this notification, it will be necessary to request an extension
If you have any questions or require assistance, please contact the Office o f Sponsored Programs
at 895-1357.

cc; OSP File

Office of SQonsoreo Progrôrrs
aSOs Marv;arc Parxwav • Ecx 451037 • Las Veoas. 'Jsvzca 8Sl54-‘ 037
!7Q2: SS5-t357 • P.AX (702 895-4242
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PROTOCOL FORM APPR0V.4L SHEET
FOR RESEARCH INVOLVING H13JAN SUBJECTS

Log N u m b e r

12 September 2000_

Title o f Projea;
Variables related to how much o f the informed consent document is read by clinical drug
research subjects
Investigator
Joanne Robinson _________________

After reviewing this proposal, the members o f the _Departraent ofNursing, Human
Subjects Rights Review Committee has indicated below their approval/disapproval of this
oroposal.
Approve Disapprove

Signature o f Committee Members

'Cut.
iX

—

-

The above named project is herebjv^ p r o v ^ disapproved (circle one).

;T
Date; A

JÙ .

i ■

-/

'■—

tz.

■/

Comrm'tt’eé^Chairperson's Signature

Decartr-ert of Nursing
i w iQ i y > o < iiiA '

•w

*

w o<3

■ Q w »o< d.

»w

(702) 8=5-3360 • FAX (702) 895-1807
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OHI O CL I NI CAL R E S E A R C H
5'S7 ‘Ja io c

S iE ;:Z . j t e v s l 2— H 'Z i

iiJSîÆÛrsr is-êâtac-

October 25.2000
Joame Rotuuon. RN
S40 R Rancho Dm cSoiie A
Las Vegas. MV 89106-3820

0

RE Data Collection
DearMs. Rofaioson.
I lecetv-ed your leques to love HoliyRenoer. RM assstyoam daa collection for raur thesis tonards a
master's degree m tnssmg. .^fiercaieiiiilT levtcnfiogyoitr request, the consent fiitin. and qaesttoioBiies
sncpiiel I felt it reasonaUe that the resescfa be conducted at Ohio CImicai Research. LLC
If I can be of fuiiber assisiaticsjsiease contaa toe at (440) 684-8900.
Sinceteiy.

Terence Isakov. MD
Pcinocnl Investigator
Cc î&IIv Renner. .RN
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SOUTHWEST MEDICAL ASSOCIATES, INC
Clinical Trials Department
Stephen H. Nfiller, MJ). Principal hivesrigator
2316 W. Charleston Blvd., Suite 280
Las Vegas, NV 89102
Phone: 702-877-8675 Fax: 702-821-1322
October:. 2000
Joanne Robinson
2316 West Charleston Blvd.
Suite 280
Las Vesas, Nevada 89102

Re: Data collection for Master s Thesis
Dear Joanne:
You have tny permission to approach patients at this research site for the purpose of
obtaining data for mur master’s thesis on imormed consent It is understood that all
patients will be informed that their participation is voluntary and not related to their
participation in the pharmaceuncal studies.
Sincerelv
Dr. Stephaî^. Miller. MD
Prindoam vktiaator
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WILLUM S. 30SSAK. MJ)-. LTD.
3115 SOCTH E.UTEHX .WENCï
U S VECAS. XEV.AD.*. S910M3ST
Teicpbene73l>U40

October 2.2000
Joanne Robinson
2316 W. Charleston Blvd
Suite 280
Las Vegas, N \' 89102
RE: Data collection for master’s thesis
Dear Ms. Robinson:
: have considered your request for permission to collect data for you .Master's thesis on
variables relating to the amount of consent form read by clinical research subjects. You
have my permission to approach patients at this site for the purpose of obtaining this data.

William S. Bossak, .\LD.
Princinal mvestizator
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UM ¥
Research Subject Information and Consent Form
TITLE:

Variables Related to How Much o f the Informed Consent
Document Is Read By Clinical Research Subjects

INVESTIGATOR: Joanne Robinson RN, ESN
Department of Nursing
University ofNevada, Las Vegas
You are being invited to participate in a research study about informed consent in drug
studies because you are currently taking part in a drug study. The following information
describes the study and your role as a study participant The research nurse will answer
any questions you have about this consent form and about the study. Please read the
consent form careftilly and do not hesitate to ask questions about the information
provided.
PURPOSE OF THE STUDY
The purpose of this study is to identiA- how much of the consent form clinical research
subjects read when they agree to participate in a drug study .An additional goal of the
study is to learn more about why research subjects read or do not read all o f the consent
form.
DESCRIPTION OF THE STUDY
•After you have completed your routine visit for the drug study you will be asked to
complete two questionnaires It will take you approximately '/i to % hour to complete
both. One of the questionnaires will ask questions about how much of the consent form
you read for the drug study you are now participating im The second questionnaire will
ask you about health care decision making. After you complete the questionnaire place
them in the attached envelope, seal it and return it to the research nurse. Approximately
100 subjects will be enrolled in this study.
POTENTIAL RISKS AND DISCOMFORTS
Risks are minimaL Participants may feel some discomfort answering some of the
questions and have the option to stop at any time and not hand in the questionnaire
POSSIBLE BENEFITS
Information gained may be benencial to health professionals concerned with the
protection o f human subjea's rights in clinical research studies.

Deoartment of Nursing
■iSOS MaryianO Pa.v.vay • Sox453013 • '_as Vegas. Nevaca 59:54-3015
rrnoi aosjyaeft •
ri.ooi
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PAYMENT FO R PARTICIPATION
You will not receive any compensatioE for participation in this study.
CONFIDENTIALITY
Information from this study will be confidennal. Your name will appear on this consent
form but not the questionnaires and the consent forms will be kept separate from all other
study information and will be stored in a locked cabinet located in the researchers office
and destroyed three years after the conclusion o f the study. Information from this study
may be presented at meetings or in publications; however, your identity will not be
disclosed in those presentations.
VOLUNTARY PARTICIPATIONAVITHDRAWAL
Your participation in this study is voluntary. You may decide not to participate or you
may withdraw from the study at any time without penalty and without affecting your
participation in the drug study.
QUESTIONS
If you have questions about this research or your participation in this study contact:
Joanne Robinson, the Department o f Nursing, UNLV @ 702-895-3360. If you have
questions about your rights as a research subject, you may contact: University o f Nevada
Las Vegas, Office o f Sponsored Programs @ 702-895-1357.
Do not sign this consent form unless you have had a chance to ask questions and have
received satismctory answers to aU o f your questions
CONSENT
I have read and I understand the information in this consent form describing this study
All my questions regarding the study and my participation in it have been answered to
my satisfaction. I freely give my consent to participate in this study until I decide
otherwise.
I understand that I will receive a copy o f this signed and dated consent form for my
records.

Subject Name (Primed)

Subjea Signature

Date
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Demographic Daia Form
By Joanne Robinson
Please indicate your answer to the following questions with an “X”. These
questions ^ l y to the clinical research s tu ^ you are participating in for a
pharmaceutical company to test a new drug.
1. How much o f the informed consent document for the drug study you are
participating in now did you read before signing it?
(
(
(
(
(

) I did not read any of the consent form.
) I read a little o f it (1/4 or less)
) I read some of it (1/4 to 1/2)
) I read most of it (1/2 to 3/4)
) I read all of it

If you did not read the entire consent form check aU that apply.
( ) Someone in the research department explained, the drug smdy to me so
I didn’t think I needed to read the entire consent form.
( ) My doctor suggested I take part in the drug study and I trust his/her
judgment so I didn’t read the entire consent form.
( ) A fiiend or family member read the consent form and explained it to
me so I didn’t read the entire form.
( ) I got information about the research study from a source other than the
consent form.
( ) I wasn’t in the mood to read the entire drug smdy consent form.
( ) Other_______________________________________________
2. Please answer Yes or ^ to the followmg statements about the consent
form for the drug study you are participating m now.
(
(
(
(
(
(
(

)Yes
)Yes
)Yes
)Y'es
)Y'es
)Yes
)Yes

(
(
(
(
(
(
(

) No
) No
)N o
)N o
)N o
)N o
)N o

The consent form was too long.
The type m the consent form was difficult to read.
I did not have e n o i^ time to read the entne consent.
I felt rushed to read the consent form.
The consent form was boring
The consent form was clear.
I received all die information I wanted about the study.
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3. How mricàoftiie consent fimnfiirtbe drug study did you understand.
(
(
(
(
(

) None of it
)AIittleofit (1/4 or less)
) Some of it (1/4 to )
) Most of it (1/2 to %)
) Mof r L

4. Were there any pans ofthe drug study consent fmmtiiatwere vague or
not clear?

OYes
()No
If you answered v « to the above question please chedcaO statements that
apply.
( ) The cfflisent form had Windsor phrases that I did not understand.
( ) The consent form descnbedsiucfy procédures that I did not
understand.
( ) Ididnothaveadiaacetoaskquestûmsaboutairytbingldidnot
understand.
( ) I was embarrassed to ask questions.
5. Did you ask any questions about die drug study before you signed the
consent form?
O Y es
()No

Please go to page 3
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6. Why did you agree to be in the drag study? Please check aU the reasons
that apply.
( ) My doctor said it would be a good idea.
( ) My family t h o u g h was a good idea.
( ) It gave me a chmice get medication that is not available at
pharmacies yet
( ) The study pays money to me for participatioiL
( ) I thought it m i ^ help other people.
( ) Fve tried every other treatment or medicme for my condition and
nothing else has helped.
( ) This is a chance to get medical care that I could not otherwise afford
to pay for
( ) I diought it would be mteresting
( ) I did not want to go against my doaor's or nurse’s recommendation to
go into the drug study.
( ) I thought it would please my doctor or nurse.
( ) Other (fill in )__________________
7. How much o f the information that you wanted about the drug study did
you receive?
(
(
(
(
(

)
)
)
)
)

None
A little ofthemformation I wanted (1/4 or less)
Some o f the information that I wanted (1/4 to ‘/:)
Most o f tiie information that I wanted (1/2 to %)
All of the information that 1wanted

8. I would participate in another drug study agam because o f my satisfaction
with this study.
( ) Yes
( ) Maybe
( ) No

Please go to page 4
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9. Have you ever been in a drug study before?
( ) Yes
()No
10. My age is:___________________
11. Gender
( )M ale
( ) Female
12. My marital status is:
(
(
(
(
(

) Single
) Married
) Divorced
) Widowed
) Other__________________________

13. The highest level of education I have completed is:
C ) Less than high school
( ) High school
( ) Some college
( ) College degree
( ) Some graduate smdy
( ) Graduate degree
( ) Technical training
14. Ethnic group
( ) Afiican-American
( ) American Indian/Alaskan
( ) Asian/Pacific Islander
( ) Caucasian
( ) Hispanic
( ) Odier

Please go to page 5
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15. What is your occupation?
) Casino
) Clerical
) Construction
) Homemaker, not employed
) Professional, e.g. architects, engineers, health professional, or teachers
)Retned
) Sales
) Service, e.g waitress, cook, janitor, hair dresser
) Technicians, e.g. computer programmer, health technician
)Otiier________________________________________

Thank You, you have completed this questionnaire
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Patient Self-Advocacy Scale
By D. Brasher

The following questions ask about your feelings about your health care. For each
of the following questions, please indicate your level of agreement with the
statement by drding either
Strongly agree. Agree, Neutral, Disagree or
Strongly disagree.
1 .1believe it is important for persons with an illness to learn as much as they can
about the disease and treatments.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

Disagree

Strongly disagree

2 . 1actively seek out information on my health.
Strongly agree

Agree

Neutral

3 .1am more educated about my health than most U.S. citizens.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

4 . 1have full knowledge of the health problems of people like me.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

Disagree

Strongly disagree

5 . 1keep notes about my illness and treatment
Strongly agree

Agree

Neutral

6 . 1research the latest treatments for my illness.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

7 . 1don’t get what 1need from my physician because I am not assertive enough.

Strongly agree

Agree

Neutral

Disagree

Strongly disagree

8 . 1am more assertive about my health care needs than most U.S. citizens.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

9.1 frequently make suggestions to my physician about my health care need.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree
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1 0 .1frequently offer my doctor suggestions about my care and treatm ent
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

Disagree

Strongly disagree

11.1 ask a lot of questions of my doctor.
Strongly agree

Agree

Neutral

12. If my physician prescribes something I don't understand or agree with, I
question it
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

13. Sometimes there are good reasons not to follow the advice of a physician.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

14. If 1am given a treatment by my physician that 1don't agree with, I am likely
not to take it
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

1 5 .1don’t always do what my physician or health care worker has asked me to
do.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

16. Sometimes I think I have a better grasp of what I need medically than my
doctor does.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

17. My doctor works for me. 1would find another doctor if I weren’t satisfied with
my health care.
Strongly agree

Agree

Neutral

Disagree

Strongly disagree

1 8 .1make my own decisions about what treatments I will or will not use, even if
my doctor prescribes it
Strongly agree

Agree

Neutral

Disagree

Strongly disagree
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